Announcements Trials
Browse Landscape

Phase

Phase 2 56Phase 3 38Phase 1/2 22Phase 1 18Phase 4 1

Status

Recruiting 3Completed 3Unknown 2Withdrawn 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Human Papillomavirus Recombinant Vaccine nonavalent 5Prednisone 3Dexamethasone 3Cisplatin 3Atorvastatin 3olaparib 2lorlatinib 2human papillomavirus vaccine, L1 type 16, 18 2enzalutamide 2adacel 2Tobacco Use Cessation Devices 2Tetanus Toxoid 2Papillomavirus Vaccines 2Letrozole 2Diphtheria-Tetanus-acellular Pertussis Vaccines 2Diphtheria Toxoid 2Denosumab 2Carboplatin 2Anesthesia, Epidural 2Abiraterone Acetate 2xiapex 1venetoclax 1tirbanibulin 1tenofovir alafenamide 1sofosbuvir-velpatasvir drug combination 1ruxolitinib 1ribociclib 1radium Ra 223 dichloride 1pembrolizumab 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Active not recruiting × Lenalidomide × Clear all
NCT03829371 2025-12-03

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

University of Turin, Italy

Phase 4 Active not recruiting
450 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡